3D Signatures (TSXV:DXD; OTCQB:TDSGF; FSE:3D0) has processed and analyzed the first batch of blood samples for the PRECISE prostate cancer trial at its new laboratory and corporate headquarters in the MaRS Discovery District in Toronto.
In a statement, Jason Flowerday, CEO of 3DS, said PRECISE trial for prostate cancer diagnosis and management provides 3DS with a “powerful opportunity to help validate Telo-PC as a first-of-its-kind test, which is able to identify if a patient has clinically significant prostate cancer and, if so, should be prioritized for treatment.”
Telo-PC is a blood-based diagnostic test for prostate cancer, which is based on the company’s proprietary TeloView software platform. Recent clinical results indicate that Telo-PC is a promising candidate for an accurate and minimally invasive risk-assessment and monitoring platform, with significant benefits over existing testing options, he added.
Telo-PC analyzes circulating tumor cells from a patient’s blood and recently demonstrated the ability to do so at all stages of prostate cancer. The test is designed to determine the status/aggressiveness of prostate cancer, which includes identification and assessment of multiple tumor subtypes within a single patient, increasing the scope of understanding of the patient’s disease status.
In addition, Telo-PC has the ability to monitor disease status by assessing tumor cells before and after treatment. The technology has identified structural changes in tumor subpopulations as a result of certain treatment regimes. The changes identified are specific to each tumor subpopulation and treatment.
